Consensus survey for MRD in MM

Dear Expert,


We are conducting a consensus survey to establish expert recommendations on minimal residual disease (MRD)-adapted therapy, focusing on clinical practice in multiple myeloma (MM). Your valuable insights will help guide clinical practice in this field. The consensus survey is divided into 4 sections, and we kindly ask you to provide your expert opinions for each by March 1st.

 

Please note that all responses are confidential and will be analyzed anonymously. We sincerely appreciate your time and expertise.

Please complete the following personal information.
Your Name

Section 1: Upgrading treatment goals in the era of CD38-based therapy for patients with multiple myeloma (MM)

Question 1: If available, do you agree that minimal residual disease (MRD) testing should be performed for all patients with MM?

Please let us know if you consider any relevant factors or remarks that should be taken into account.

Section 1: Upgrading treatment goals in the era of CD38-based therapy for patients with multiple myeloma (MM)

Question 2: Do you agree that MRD assessment should be incorporated into the treatment evaluation process for patients with MM?
Please let us know if you consider any relevant factors or remarks that should be taken into account.
Section 1: Upgrading treatment goals in the era of CD38-based therapy for patients with multiple myeloma (MM)
Question 3: Do you agree that achieving and maintaining MRD negativity leads to a better prognosis in patients with MM receiving CD38-based therapy?
Please let us know if you consider any relevant factors or remarks that should be taken into account.
Section 2: MRD status guidance for clinical decision-making
Question 1: Do you agree that the timing and frequency of MRD assessments should be tailored according to the treatment phase for patients with MM?
Please let us know if you consider any relevant factors or remarks that should be taken into account.
Section 2: MRD status guidance for clinical decision-making
Question 2: Do you agree that maintenance therapy may be discontinued in patients with sustained MRD negativity, and that therapeutic intervention should be resumed upon MRD conversion to positivity?
Please let us know if you consider any relevant factors or remarks that should be taken into account.
Section 2: MRD status guidance for clinical decision-making
Question 3: Based on MRD status, do you agree that a CD38-based quadruplet regimen could potentially serve as an alternative to transplant?
Please let us know if you consider any relevant factors or remarks that should be taken into account.
Section 2: MRD status guidance for clinical decision-making
Question 4: Based on MRD status, do you agree that CD38-based therapy could be used for active maintenance therapy?
Please let us know if you consider any relevant factors or remarks that should be taken into account.
Section 2: MRD status guidance for clinical decision-making
Question 5: Do you agree that dynamic MRD monitoring will provide a more precise application in future clinical practice?
Please let us know if you consider any relevant factors or remarks that should be taken into account.
Section 3: Standardization and normalization of MRD detection
Question 1: Do you agree that next-generation flow cytometry (NGF) and next-generation sequencing (NGS) are largely interchangeable for prognostic assessment of MRD status in MM when performed at validated sensitivity thresholds?
Please let us know if you consider any relevant factors or remarks that should be taken into account.
Section 4: Development of new detection technologies and possible solutions
Question 1: Do you agree that peripheral residual disease (PRD) detection will become a key direction for future disease monitoring?
Please let us know if you consider any relevant factors or remarks that should be taken into account.
Thank you for completing the questionnaire. Your input will contribute to the development of expert consensus guidelines for MRD-adapted therapy in MM. If you have any additional comments or suggestions, please feel free to share them below.
I hereby certify that the information provided in this survey is complete, true and correct to the best of my knowledge.
更多问卷 复制此问卷